University of Arizona researchers have developed a new therapy for Alzheimer’s disease designed to restore cognitive function in early-stage patients. The therapy is now proceeding through a Phase 2b clinical trial.
Phase 2b trials involve rigorous testing for efficacy in groups of 100 to 300 patients.
The team, led by Roberta Diaz Brinton, director of the UArizona Health Sciences Center for Innovation in Brain Science and a member of the BIO5 Institute, found that the neurosteroid allopregnanolone, or allo, used to treat women with postpartum depression, promotes…